2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-D1056B2
    Lipopolysaccharides, from Proteus mirabilis
    Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma.
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from Proteus mirabilis
  • HY-E70365A
    IdeS (Immobilized, Microspin)
    IdeS (Immobilized, Microspin) is a resin that covalently couples IdeS protease to agarose beads and cleaves IgG at specific sites to generate F(ab')2 and Fc fragments. After IdeS (Immobilized, Microspin) digestion, F(ab')2 and Fc fragments are obtained in the solution without IdeS enzyme.
    IdeS (Immobilized, Microspin)
  • HY-N0007AR
    Bisdemethoxycucurmin (Standard) 24939-16-0 98.33%
    Bisdemethoxycucurmin (Standard) (Curcumin III (Standard)) is the analytical standard of Bisdemethoxycucurmin (HY-N0007A). This product is intended for research and analytical applications. Bisdemethoxycucurmin (Curcumin III) is a curcuminoid compound and an inhibitor of P-glycoprotein and ferroptosis. Bisdemethoxycucurmin exhibits multiple activities such as anti-oxidation, anti-inflammation and anti-tumor. Bisdemethoxycucurmin can be used for the research of tumors and inflammatory diseases.
    Bisdemethoxycucurmin (Standard)
  • HY-N0390S7
    L-Glutamine-15N2,d5 98%
    L-Glutamine-15N2,d5 is the deuterium and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
    L-Glutamine-15N2,d5
  • HY-N0832S1
    L-Histidine-13C6,15N3 741656-40-6 98%
    L-Histidine-13C6,15N3 is 13C and 15N-labeled L-Histidine (HY-N0832). L-Histidine is an essential amino acid for infants. L-Histidine is an inhibitor of mitochondrial glutamine transport.
    L-Histidine-13C6,15N3
  • HY-N10634S
    D-Glucosyl-β-N-palmitoylsphingosine-d3 71924-12-4 98%
    D-Glucosyl-β-N-palmitoylsphingosine-d3 (N-ω-CD3-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine (HY-N10634). D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity.
    D-Glucosyl-β-N-palmitoylsphingosine-d3
  • HY-N6020AR
    (+)-Butin (Standard) 74628-42-5 98.82%
    (+)-Butin (Standard) is the analytical standard of (+)-Butin (HY-N6020A). This product is intended for research and analytical applications. (+)-Butin is the R-enantiomer of Butin (HY-N6020B). Butin is a bioactive flavonoid. Butin can be isolated from the heartwood of Dalbergia cocos. Butin exhibits potent antioxidant, antiplatelet, and anti-inflammatory activities.
    (+)-Butin (Standard)
  • HY-P10462A
    SAP15 acetate 98.04%
    SAP15 (Synthetic anti-inflammatory peptide 15) acetate is a synthetic anti-inflammatory peptide consisting of 15 amino acids designed from human beta-defensin 3. SAP15 acetate has the ability to penetrate cells and is able to induce downregulation of intracellular inflammation. SAP15 acetate inhibits inflammation by inhibiting the phosphorylation of HDAC5 and thereby reducing the phosphorylation of NF-κB p65. SAP15 acetate inhibits HDAC5 and NF-κB p65 phosphorylation in LPS (HY-D1056)-induced macrophages. SAP15 acetate increases the expression of aggrecan and type II collagen and decreases the expression of osteocalcin in LPS-induced chondrocytes. SAP15 acetate can be used in the study of inflammation regulation and anti-inflammatory therapy of biomaterials.
    SAP15 acetate
  • HY-P10497A
    EBV BZLF1 (190-197) TFA 98.74%
    EBV BZLF1 (190-197) TFA is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) TFA is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) TFA are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) TFA can be used to study autoimmune diseases.
    EBV BZLF1 (190-197) TFA
  • HY-P10587A
    Icotrokinra acetate 99.65%
    Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
    Icotrokinra acetate
  • HY-P10587B
    Icotrokinra (hydrochloride) 99.74%
    Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
    Icotrokinra (hydrochloride)
  • HY-P10768B
    Ro 25-1553 acetate 98%
    Ro 25-1553 acetate is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 acetate exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 acetate produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 acetate can be used for the study of bronchoconstriction.
    Ro 25-1553 acetate
  • HY-P10966A
    Tat-IKIP (46-60) TFA 99.76%
    Tat-IKIP (46-60) TFA is the trifluoroacetic acid of Tat-IKIP (46-60) (HY-P10966). Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis.
    Tat-IKIP (46-60) TFA
  • HY-P11108A
    RP-182 acetate 98%
    RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 acetate induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 acetate has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 acetate is used in pancreatic cancer and melanoma research.
    RP-182 acetate
  • HY-P11187A
    Bactofencin A acetate 99.26%
    Bactofencin A acetate is a class IId bacteriocin and Antibacterial agent. Bactofencin A acetate is produced by Lactobacillus salivarius DPC6502, an isolate derived from the intestine. Bactofencin A acetate exhibits activity against Staphylococcus and Listeria species. Bactofencin A acetate slightly modulates the intestinal flora. Bactofencin A acetate can be used in research related to staphylococcal infections, listerial infections, and mastitis.
    Bactofencin A acetate
  • HY-P11553A
    ECL1i TFA
    ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis.
    ECL1i TFA
  • HY-P11553B
    DOTA-ECL1i 2850189-48-7 98.06%
    DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.
    DOTA-ECL1i
  • HY-P11636A
    TRP-1(106-130) acetate 98%
    TRP-1(106-130) acetate is a peptide sequence derived from tyrosinase-related protein 1 (TRP-1), which can be used to specifically activate and amplify T cells that recognize this antigen sequence.
    TRP-1(106-130) acetate
  • HY-P11638A
    Mitochondrial-targeted peptide BP29 acetate 98.15%
    Mitochondrial-targeted peptide BP29 acetate is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 acetate protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 acetate prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 acetate can be used for the research of Friedreich's ataxia.
    Mitochondrial-targeted peptide BP29 acetate
  • HY-P11642A
    Sialorphin TFA
    Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease.
    Sialorphin TFA
Cat. No. Product Name / Synonyms Application Reactivity